PUBLISHER: Inkwood Research | PRODUCT CODE: 1091873
PUBLISHER: Inkwood Research | PRODUCT CODE: 1091873
The United States medical enzymes market is evaluated to rise with a CAGR of 6.43% across the forecasted period. While the base year regarded for the studied market is 2021, the estimated years are from 2022 to 2028. The country's market growth is mainly ascribed to increasing consciousness about health and personal care, technological developments and innovations, and extensive research activities linked to medical enzymes.
Enzymes are characterized as biocatalysts with the potential to alter the rate of reaction. On the other hand, it also produces the desired results in biological reactions. Medical enzymes are primarily utilized to eliminate disease-causing microorganisms, diagnose certain diseases, and promote wound healing. Moreover, enzyme technology is further being employed for the treatment of major conditions, such as cancer, lysosomal ailments, and metabolic diseases.
The presence of top players operating in the United States plays a vital role in fueling the country's medical enzymes market. In this regard, the partnerships, collaborations, and product launches initiated by these companies are essential for the country's market growth, as well. For example, Nestle Health Science and Codexis partnered for the discovery of novel enzyme therapies. The collaboration primarily focused on the treatment of gastrointestinal disorders. Likewise, Codexis further extended its partnership with Tate and Lyle, a global supplier of food and beverage ingredients. As a result, these factors are anticipated to proliferate the medical enzymes market growth in the United States during the forecast years.
Key players operating in the market are: Novus, DSM, Thermo Fisher Scientific, etc.